In this episode, Dr. Ravindra Uppaluri, Dr. Dylan Roden, and Dr. Adam Luginbuhl discuss the implications of the KEYNOTE-689 trial and what its FDA approval means for the management of locally advanced head and neck cancer. The conversation explores trial design, CPS scoring, and practical implementation strategies for neoadjuvant pembrolizumab in real-world clinical settings. The experts share insights on multidisciplinary coordination, patient selection, and how structured treatment pathways can help streamline care while maintaining close surgical oversight during immunotherapy cycles.
Contributors:
Dr. Adam Luginbuhl is an Associate Professor of Otolaryngology Head and Neck Surgery at Thomas Jefferson University.
Dr. Dylan Roden is a head and neck cancer surgeon and Chair of Robotic Surgery at Rutgers New Jersey Medical School.
Dr. Ravindra Uppaluri is the Director of Head and Neck Surgical Oncology at the Brigham and Women’s Hospital in Boston, Massachusetts.
